Australia markets close in 2 hours 56 minutes

ASLAN Pharmaceuticals Limited (ASLN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.5400+0.0490 (+9.98%)
At close: 04:00PM EDT
0.5200 -0.02 (-3.70%)
After hours: 07:43PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 12.22M
Enterprise value 17.79M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.74
Price/book (mrq)2.14
Enterprise value/revenue 1.48
Enterprise value/EBITDA -0.45

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-86.43%
S&P500 52-week change 321.23%
52-week high 34.6900
52-week low 30.3920
50-day moving average 30.6103
200-day moving average 31.2298

Share statistics

Avg vol (3-month) 31M
Avg vol (10-day) 3160.26k
Shares outstanding 522.63M
Implied shares outstanding 624.38M
Float 8371.91M
% held by insiders 10.05%
% held by institutions 115.49%
Shares short (28 Mar 2024) 4116.78k
Short ratio (28 Mar 2024) 40.05
Short % of float (28 Mar 2024) 40.52%
Short % of shares outstanding (28 Mar 2024) 40.52%
Shares short (prior month 29 Feb 2024) 419.33k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:5
Last split date 313 Mar 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-364.46%

Management effectiveness

Return on assets (ttm)-63.71%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)12M
Revenue per share (ttm)0.75
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -43.39M
Net income avi to common (ttm)-44.22M
Diluted EPS (ttm)-2.7500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)21.25M
Total cash per share (mrq)0.05
Total debt (mrq)26.83M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.84
Book value per share (mrq)-0.77

Cash flow statement

Operating cash flow (ttm)-46.64M
Levered free cash flow (ttm)-32.72M